vs
Side-by-side financial comparison of Hologic (HOLX) and RH (RH). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $883.8M, roughly 1.2× RH). Hologic runs the higher net margin — 17.1% vs 4.1%, a 13.0% gap on every dollar of revenue. On growth, RH posted the faster year-over-year revenue change (8.9% vs 2.5%). Hologic produced more free cash flow last quarter ($215.2M vs $83.0M). Over the past eight quarters, RH's revenue compounded faster (9.4% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
RH is an upscale American home-furnishings company headquartered in Corte Madera, California. The company sells its merchandise through its retail stores, catalog, and online. As of August 2018, the company operated a total of 70 galleries, 18 full-line design galleries, and 3 baby-and-child galleries. The company also has 36 outlet stores in the United States and Canada.
HOLX vs RH — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $883.8M |
| Net Profit | $179.1M | $36.3M |
| Gross Margin | 56.0% | 44.1% |
| Operating Margin | 22.6% | 12.0% |
| Net Margin | 17.1% | 4.1% |
| Revenue YoY | 2.5% | 8.9% |
| Net Profit YoY | -10.9% | 9.3% |
| EPS (diluted) | $0.79 | $1.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $883.8M | ||
| Q3 25 | $1.0B | $899.2M | ||
| Q2 25 | $1.0B | $814.0M | ||
| Q1 25 | $1.0B | $812.4M | ||
| Q4 24 | $1.0B | $811.7M | ||
| Q3 24 | $988.0M | $829.7M | ||
| Q2 24 | $1.0B | $727.0M | ||
| Q1 24 | $1.0B | $738.3M |
| Q4 25 | $179.1M | $36.3M | ||
| Q3 25 | $187.2M | $51.7M | ||
| Q2 25 | $194.9M | $8.0M | ||
| Q1 25 | $-17.4M | $13.9M | ||
| Q4 24 | $201.0M | $33.2M | ||
| Q3 24 | $178.6M | $29.0M | ||
| Q2 24 | $194.5M | $-3.6M | ||
| Q1 24 | $169.9M | $11.4M |
| Q4 25 | 56.0% | 44.1% | ||
| Q3 25 | 55.6% | 45.5% | ||
| Q2 25 | 56.3% | 43.7% | ||
| Q1 25 | 37.5% | 44.7% | ||
| Q4 24 | 56.8% | 44.5% | ||
| Q3 24 | 56.4% | 45.2% | ||
| Q2 24 | 55.4% | 43.5% | ||
| Q1 24 | 53.3% | 43.5% |
| Q4 25 | 22.6% | 12.0% | ||
| Q3 25 | 22.6% | 14.3% | ||
| Q2 25 | 24.9% | 6.9% | ||
| Q1 25 | -0.7% | 8.7% | ||
| Q4 24 | 22.5% | 12.5% | ||
| Q3 24 | 23.3% | 11.6% | ||
| Q2 24 | 24.1% | 7.5% | ||
| Q1 24 | 20.7% | 8.7% |
| Q4 25 | 17.1% | 4.1% | ||
| Q3 25 | 17.8% | 5.8% | ||
| Q2 25 | 19.0% | 1.0% | ||
| Q1 25 | -1.7% | 1.7% | ||
| Q4 24 | 19.7% | 4.1% | ||
| Q3 24 | 18.1% | 3.5% | ||
| Q2 24 | 19.2% | -0.5% | ||
| Q1 24 | 16.7% | 1.5% |
| Q4 25 | $0.79 | $1.83 | ||
| Q3 25 | $0.84 | $2.62 | ||
| Q2 25 | $0.86 | $0.40 | ||
| Q1 25 | $-0.08 | $0.71 | ||
| Q4 24 | $0.87 | $1.66 | ||
| Q3 24 | $0.75 | $1.45 | ||
| Q2 24 | $0.82 | $-0.20 | ||
| Q1 24 | $0.72 | $0.91 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $43.1M |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $5.2B | $3.3M |
| Total Assets | $9.2B | $4.8B |
| Debt / EquityLower = less leverage | 0.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | $43.1M | ||
| Q3 25 | $2.2B | $34.6M | ||
| Q2 25 | $1.9B | $46.1M | ||
| Q1 25 | $1.6B | $30.4M | ||
| Q4 24 | $2.0B | $87.0M | ||
| Q3 24 | $2.3B | $78.3M | ||
| Q2 24 | $2.4B | $101.8M | ||
| Q1 24 | $2.2B | $123.7M |
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.6B | — |
| Q4 25 | $5.2B | $3.3M | ||
| Q3 25 | $5.0B | $-40.9M | ||
| Q2 25 | $4.8B | $-110.8M | ||
| Q1 25 | $4.6B | $-163.6M | ||
| Q4 24 | $4.8B | $-183.0M | ||
| Q3 24 | $5.1B | $-234.7M | ||
| Q2 24 | $5.0B | $-289.9M | ||
| Q1 24 | $4.8B | $-297.4M |
| Q4 25 | $9.2B | $4.8B | ||
| Q3 25 | $9.0B | $4.7B | ||
| Q2 25 | $8.8B | $4.7B | ||
| Q1 25 | $8.5B | $4.6B | ||
| Q4 24 | $8.7B | $4.5B | ||
| Q3 24 | $9.2B | $4.4B | ||
| Q2 24 | $8.9B | $4.2B | ||
| Q1 24 | $8.7B | $4.1B |
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 0.53× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $131.9M |
| Free Cash FlowOCF − Capex | $215.2M | $83.0M |
| FCF MarginFCF / Revenue | 20.5% | 9.4% |
| Capex IntensityCapex / Revenue | 1.4% | 5.5% |
| Cash ConversionOCF / Net Profit | 1.28× | 3.64× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $128.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | $131.9M | ||
| Q3 25 | $355.1M | $137.7M | ||
| Q2 25 | $343.3M | $86.6M | ||
| Q1 25 | $169.4M | $-18.8M | ||
| Q4 24 | $189.3M | $-31.4M | ||
| Q3 24 | $367.0M | $11.2M | ||
| Q2 24 | $405.8M | $56.1M | ||
| Q1 24 | $292.4M | $-114.0M |
| Q4 25 | $215.2M | $83.0M | ||
| Q3 25 | $341.4M | $80.7M | ||
| Q2 25 | $330.5M | $34.1M | ||
| Q1 25 | $153.9M | $-69.7M | ||
| Q4 24 | $172.5M | $-96.0M | ||
| Q3 24 | $350.6M | $-37.9M | ||
| Q2 24 | $385.3M | $-10.1M | ||
| Q1 24 | $279.6M | $-251.5M |
| Q4 25 | 20.5% | 9.4% | ||
| Q3 25 | 32.5% | 9.0% | ||
| Q2 25 | 32.3% | 4.2% | ||
| Q1 25 | 15.3% | -8.6% | ||
| Q4 24 | 16.9% | -11.8% | ||
| Q3 24 | 35.5% | -4.6% | ||
| Q2 24 | 38.1% | -1.4% | ||
| Q1 24 | 27.5% | -34.1% |
| Q4 25 | 1.4% | 5.5% | ||
| Q3 25 | 1.3% | 6.3% | ||
| Q2 25 | 1.3% | 6.5% | ||
| Q1 25 | 1.5% | 6.3% | ||
| Q4 24 | 1.6% | 8.0% | ||
| Q3 24 | 1.7% | 5.9% | ||
| Q2 24 | 2.0% | 9.1% | ||
| Q1 24 | 1.3% | 18.6% |
| Q4 25 | 1.28× | 3.64× | ||
| Q3 25 | 1.90× | 2.66× | ||
| Q2 25 | 1.76× | 10.78× | ||
| Q1 25 | — | -1.35× | ||
| Q4 24 | 0.94× | -0.95× | ||
| Q3 24 | 2.05× | 0.39× | ||
| Q2 24 | 2.09× | — | ||
| Q1 24 | 1.72× | -10.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
RH
| RH Segment | $835.8M | 95% |
| Waterworks Segment | $48.0M | 5% |
| Gift Card And Merchandise Credit | $4.5M | 1% |
